CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SOCS2-AS1 (ImmuneEditome ID:144481)

1. Gene summary of enriched editing regions for SOCS2-AS1

check button Gene summary
Gene informationGene symbol

SOCS2-AS1

Gene ID

144481

GeneSynonyms-
GeneCytomap

12q22

GeneTypencRNA
GeneDescriptionSOCS2 antisense RNA 1 (non-protein coding)
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr12:93542505-93543137:-ENST00000499137.5ENSG00000246985.6SOCS2-AS1ncRNA_exonicAluJr,AluSz6chr12:93542505-93543137:-.alignment
chr12:93542505-93543137:-ENST00000500986.4ENSG00000246985.6SOCS2-AS1ncRNA_exonicAluJr,AluSz6chr12:93542505-93543137:-.alignment
chr12:93544693-93544991:-ENST00000499137.5ENSG00000246985.6SOCS2-AS1ncRNA_exonicLOR1-int,AluSzchr12:93544693-93544991:-.alignment
chr12:93565217-93565454:-ENST00000499137.5ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluJochr12:93565217-93565454:-.alignment
chr12:93565217-93565454:-ENST00000500986.4ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluJochr12:93565217-93565454:-.alignment
chr12:93565217-93565454:-ENST00000547845.4ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluJochr12:93565217-93565454:-.alignment
chr12:93568504-93569057:-ENST00000499137.5ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluSx1,L2c,AluSzchr12:93568504-93569057:-.alignment
chr12:93568504-93569057:-ENST00000500986.4ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluSx1,L2c,AluSzchr12:93568504-93569057:-.alignment
chr12:93568504-93569057:-ENST00000551626.1ENSG00000246985.6SOCS2-AS1ncRNA_intronicAluSx1,L2c,AluSzchr12:93568504-93569057:-.alignment


Top

2. Tumor-specific enriched editing regions for SOCS2-AS1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr12:93542505-93543137:-OVCliEER1.3207e-024.4827e-02-0.4317image
ENSG00000246985.6,SOCS2-AS1OVCliEAG1.4272e-022.5564e-02-0.4645image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for SOCS2-AS1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr12:93542505-93543137:-PCPGEERENSG00000143870,PDIA60.40001.7875e-041.1550e-070.4090imageNGNL3NAB_cells_naiveGSVA_HALLMARK_ANDROGEN_RESPONSE
chr12:93542505-93543137:-PCPGEERENSG00000168758,SEMA4C0.40111.7875e-041.0657e-070.4100imageNGNL3SEMA4CT_cells_CD4_memory_activatedGSVA_HALLMARK_TGF_BETA_SIGNALING
chr12:93542505-93543137:-THYMEERENSG00000142544,CTU1-0.44815.3945e-048.6349e-05-0.4061imageNGNL3NAT_cells_CD8GSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000125912,NCLN-0.43366.5178e-042.3633e-05-0.4343imageNGNL3NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000160226,C21orf2-0.44477.9801e-041.9609e-05-0.4381imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000171222,SCAND1-0.43048.8246e-049.7730e-05-0.4033imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000154305,MIA30.42999.1772e-042.2264e-050.4355imageNGNL3MIA3T_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000101199,ARFGAP1-0.43059.6998e-042.4331e-05-0.4337imageNGNL3NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000058673,ZC3H11A0.43289.7240e-042.1574e-050.4362imageNGNL3NAMast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000162923,WDR260.42281.1070e-036.2602e-060.4608imageNGNL3NAMast_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
chr12:93542505-93543137:-PCPGEERENSG00000143870,PDIA60.40001.7875e-041.1550e-070.4090imageNGNL3NAB_cells_naiveGSVA_HALLMARK_ANDROGEN_RESPONSE
chr12:93542505-93543137:-PCPGEERENSG00000168758,SEMA4C0.40111.7875e-041.0657e-070.4100imageNGNL3SEMA4CT_cells_CD4_memory_activatedGSVA_HALLMARK_TGF_BETA_SIGNALING
chr12:93542505-93543137:-THYMEERENSG00000142544,CTU1-0.44815.3945e-048.6349e-05-0.4061imageNGNL3NAT_cells_CD8GSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000125912,NCLN-0.43366.5178e-042.3633e-05-0.4343imageNGNL3NAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000160226,C21orf2-0.44477.9801e-041.9609e-05-0.4381imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000171222,SCAND1-0.43048.8246e-049.7730e-05-0.4033imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000154305,MIA30.42999.1772e-042.2264e-050.4355imageNGNL3MIA3T_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000101199,ARFGAP1-0.43059.6998e-042.4331e-05-0.4337imageNGNL3NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000058673,ZC3H11A0.43289.7240e-042.1574e-050.4362imageNGNL3NAMast_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-THYMEERENSG00000162923,WDR260.42281.1070e-036.2602e-060.4608imageNGNL3NAMast_cells_activatedGSVA_HALLMARK_HEME_METABOLISM

More results



Top

4. Enriched editing regions and immune related splicing for SOCS2-AS1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000246985.6,SOCS2-AS1
PCPGEAGESENSG00000051620.6chr6138406077:138406151:138412879:138413154:138415197:138422197-0.25583.0471e-022.8974e-07-0.4641imageNADAR;BCCIP;CPSF6;CSTF2T;DDX42;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28B;LSM11;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2NANK_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-
PCPGEERESENSG00000051620.6chr6138406077:138406151:138412879:138413154:138415197:138422197-0.25583.2653e-022.8974e-07-0.4641imageNGNL3NANK_cells_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr12:93542505-93543137:-
THYMEERMEXENSG00000111057.6chr1252950749:52950906:52951480:52951531:52951618:52951645:52951730:529518560.38643.3953e-027.7526e-050.4086imageNGNL3KRT18T_cells_CD4_memory_restingGSVA_HALLMARK_HEME_METABOLISM
chr12:93542505-93543137:-
THYMEERMEXENSG00000178719.12chr8143991746:143991804:143991877:143991949:143991949:143992078:143992244:1439923730.41101.8527e-023.3209e-050.4271imageNGNL3NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000246985.6,SOCS2-AS1
THYMEAGMEXENSG00000159131.12chr2133504411:33504527:33505560:33505605:33505973:33506104:33509782:33509920-0.40572.0358e-025.6211e-05-0.4157imageNADAR;BCCIP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000246985.6,SOCS2-AS1
THYMEAGMEXENSG00000109736.10chr42930602:2931150:2931226:2931274:2931554:2931936:2932044:2932153-0.46113.8811e-033.1262e-05-0.4284imageNBCCIP;CPSF6;CSTF2T;DDX42;DGCR8;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM27;SAFB2;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2;ZNF184MFSD10T_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000246985.6,SOCS2-AS1
THYMEAGA5ENSG00000198131.9chr1958243964:58244056:58230393:58230462:58230393:582304970.42891.0312e-023.8542e-060.4724imageNADAR;BCCIP;CPSF6;CSTF2T;DDX42;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MSI1;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2NAT_cells_gamma_deltaGSVA_HALLMARK_BILE_ACID_METABOLISM
chr12:93542505-93543137:-
THYMEERMEXENSG00000054611.9chr2246797443:46797620:46878652:46878723:46974289:46974399:46997633:469977090.39182.9015e-022.4401e-050.4336imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000246985.6,SOCS2-AS1
THYMEAGMEXENSG00000111057.6chr1252950749:52950906:52951480:52951531:52951618:52951645:52951730:529518560.38943.4597e-026.8279e-050.4114imageNADAR;BCCIP;CPSF6;CSTF2T;DDX42;DGCR8;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28B;LSM11;MSI1;NONO;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SLTM;SMNDC1;SRSF1;SRSF3;TAF15;TARDBP;TROVE2;U2AF2;UPF1;XRN2;ZNF184KRT18T_cells_CD4_memory_restingGSVA_HALLMARK_HEME_METABOLISM
chr12:93542505-93543137:-
THYMEERESENSG00000114956.15chr273926907:73927052:73946718:73946906:73958145:739582450.44927.3324e-039.9883e-050.4028imageNGNL3NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for SOCS2-AS1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr12:93542505-93543137:-BRCAEERT_cells_CD4_memory_activated3.7683e-030.1625image
ENSG00000246985.6,SOCS2-AS1BRCAEAGT_cells_CD4_memory_activated3.8547e-030.1619image
chr12:93542505-93543137:-CESCEERT_cells_gamma_delta7.4155e-030.4331image
ENSG00000246985.6,SOCS2-AS1CESCEAGT_cells_gamma_delta7.2439e-030.4342image
chr12:93542505-93543137:-ESCAEERT_cells_CD4_memory_resting1.1777e-020.4270image
ENSG00000246985.6,SOCS2-AS1ESCAEAGT_cells_CD4_memory_resting9.7911e-030.4368image
chr12:93542505-93543137:-GBMEERB_cells_memory6.2339e-030.2536image
ENSG00000246985.6,SOCS2-AS1GBMEAGB_cells_memory4.6089e-030.2624image
chr12:93542505-93543137:-KIRPEERDendritic_cells_resting3.4812e-02-0.3933image
ENSG00000246985.6,SOCS2-AS1KIRPEAGDendritic_cells_resting3.4812e-02-0.3933image
chr12:93542505-93543137:-LGGEERT_cells_CD4_naive2.0800e-030.3029image
ENSG00000246985.6,SOCS2-AS1LGGEAGT_cells_CD4_naive2.0750e-030.3029image
chr12:93542505-93543137:-LIHCEERDendritic_cells_resting7.8067e-030.3720image
ENSG00000246985.6,SOCS2-AS1LIHCEAGDendritic_cells_resting7.6195e-030.3731image
chr12:93542505-93543137:-LUSCEERMast_cells_resting1.9071e-020.2038image
ENSG00000246985.6,SOCS2-AS1LUSCEAGMast_cells_resting1.9964e-020.2024image
chr12:93542505-93543137:-PAADEERMacrophages_M03.3074e-020.4274image
ENSG00000246985.6,SOCS2-AS1PAADEAGMacrophages_M03.3074e-020.4274image
chr12:93542505-93543137:-PCPGEERB_cells_naive3.0663e-030.2356image
ENSG00000246985.6,SOCS2-AS1PCPGEAGB_cells_naive3.0767e-030.2355image
chr12:93542505-93543137:-PRADEERDendritic_cells_resting1.4995e-040.1703image
ENSG00000246985.6,SOCS2-AS1PRADEAGDendritic_cells_resting1.3825e-040.1710image
chr12:93542505-93543137:-SARCEERPlasma_cells8.5211e-050.4225image
ENSG00000246985.6,SOCS2-AS1SARCEAGPlasma_cells8.5973e-050.4223image
chr12:93542505-93543137:-STADEERB_cells_naive9.1546e-030.2795image
chr12:93542505-93543137:-THCAEERDendritic_cells_resting7.5529e-030.2438image
ENSG00000246985.6,SOCS2-AS1THCAEAGDendritic_cells_resting7.5529e-030.2438image
chr12:93542505-93543137:-THYMEERT_cells_CD4_memory_resting1.6484e-020.2550image
ENSG00000246985.6,SOCS2-AS1THYMEAGT_cells_CD4_memory_resting1.6227e-020.2556image


Top

6. Enriched editing regions and immune gene sets for SOCS2-AS1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000246985.6,SOCS2-AS1LGGEAG2.3530e-03-0.29941.7572e-03-0.30754.6840e-02-0.19831.2751e-02-0.2470image
chr12:93542505-93543137:-LGGEER2.3602e-03-0.29931.7597e-03-0.30754.6851e-02-0.19831.2793e-02-0.2469image
ENSG00000246985.6,SOCS2-AS1PCPGEAG4.3878e-020.16168.5714e-030.20987.6642e-030.21282.9538e-020.1743image
chr12:93542505-93543137:-PCPGEER4.4012e-020.16158.6003e-030.20977.7032e-030.21262.9523e-020.1743image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000246985.6,SOCS2-AS1BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.9293e-040.1979image
chr12:93542505-93543137:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER9.7418e-050.2174image
ENSG00000246985.6,SOCS2-AS1GBMGSVA_HALLMARK_MYOGENESISEAG3.9998e-030.2664image
chr12:93542505-93543137:-GBMGSVA_HALLMARK_DNA_REPAIREER3.6822e-03-0.2688image
ENSG00000246985.6,SOCS2-AS1HNSCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.4502e-040.7183image
chr12:93542505-93543137:-KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER4.6617e-020.2624image
ENSG00000246985.6,SOCS2-AS1LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.6130e-05-0.3863image
chr12:93542505-93543137:-LGGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.6593e-05-0.3861image
chr12:93542505-93543137:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER1.3898e-030.4399image
ENSG00000246985.6,SOCS2-AS1LIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG1.2395e-030.4440image
ENSG00000246985.6,SOCS2-AS1LUADGSVA_HALLMARK_GLYCOLYSISEAG1.4649e-02-0.3246image
chr12:93542505-93543137:-LUADGSVA_HALLMARK_GLYCOLYSISEER1.3843e-02-0.3272image
chr12:93542505-93543137:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0449e-020.2222image
ENSG00000246985.6,SOCS2-AS1LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0830e-020.2211image
ENSG00000246985.6,SOCS2-AS1PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.3055e-030.6066image
chr12:93542505-93543137:-PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.3055e-030.6066image
chr12:93542505-93543137:-PCPGGSVA_HALLMARK_HEME_METABOLISMEER3.2392e-050.3262image
ENSG00000246985.6,SOCS2-AS1PCPGGSVA_HALLMARK_HEME_METABOLISMEAG3.2165e-050.3263image
ENSG00000246985.6,SOCS2-AS1PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1190e-100.2854image
chr12:93542505-93543137:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER6.3891e-100.2743image
ENSG00000246985.6,SOCS2-AS1SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.6843e-03-0.3112image
chr12:93542505-93543137:-SARCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER8.3621e-03-0.2912image
chr12:93542505-93543137:-SKCMGSVA_HALLMARK_HEME_METABOLISMEER2.5734e-020.2027image
ENSG00000246985.6,SOCS2-AS1SKCMGSVA_HALLMARK_HEME_METABOLISMEAG2.5566e-020.2030image
chr12:93542505-93543137:-STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.6790e-02-0.2388image
ENSG00000246985.6,SOCS2-AS1THCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.9188e-030.2816image
chr12:93542505-93543137:-THCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.9188e-030.2816image
chr12:93542505-93543137:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.3429e-020.2626image
ENSG00000246985.6,SOCS2-AS1THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.3090e-020.2636image


Top

7. Enriched editing regions and drugs for SOCS2-AS1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr12:93542505-93543137:-BLCAGefitinibEER6.4843e-04-0.3711image
ENSG00000246985.6,SOCS2-AS1BLCAGefitinibEAG6.5055e-04-0.3710image
chr12:93542505-93543137:-BRCADMOGEER1.9183e-02-0.1319image
ENSG00000246985.6,SOCS2-AS1BRCADMOGEAG1.1278e-02-0.1424image
ENSG00000246985.6,SOCS2-AS1CESCElesclomolEAG8.7096e-030.4252image
chr12:93542505-93543137:-CESCElesclomolEER8.4681e-030.4266image
chr12:93542505-93543137:-ESCAGDC.0449EER3.5458e-02-0.3673image
ENSG00000246985.6,SOCS2-AS1ESCAGDC.0449EAG3.9716e-02-0.3598image
chr12:93542505-93543137:-GBMDMOGEER4.2985e-03-0.2644image
ENSG00000246985.6,SOCS2-AS1GBMDMOGEAG5.0986e-03-0.2595image
ENSG00000246985.6,SOCS2-AS1HNSCBicalutamideEAG7.4683e-03-0.5661image
chr12:93542505-93543137:-KIRPBleomycinEER4.8345e-02-0.3698image
ENSG00000246985.6,SOCS2-AS1KIRPBleomycinEAG4.8345e-02-0.3698image
chr12:93542505-93543137:-LAMLAG.014699EER3.9083e-02-0.2843image
ENSG00000246985.6,SOCS2-AS1LAMLCCT018159EAG3.4465e-02-0.2911image
chr12:93565217-93565454:-LAMLBX.795EER1.0424e-02-0.5126image
ENSG00000246985.6,SOCS2-AS1LGGBortezomibEAG3.0652e-040.3520image
chr12:93542505-93543137:-LGGBortezomibEER3.1004e-040.3517image
chr12:93542505-93543137:-LIHCBMS.708163EER1.6468e-02-0.3377image
ENSG00000246985.6,SOCS2-AS1LIHCBMS.708163EAG1.4630e-02-0.3434image
chr12:93542505-93543137:-LUADMG.132EER3.0908e-030.3885image
ENSG00000246985.6,SOCS2-AS1LUADMG.132EAG3.3403e-030.3856image
chr12:93542505-93543137:-LUSCEpothilone.BEER4.7687e-02-0.1727image
ENSG00000246985.6,SOCS2-AS1LUSCEpothilone.BEAG4.6917e-02-0.1733image
ENSG00000246985.6,SOCS2-AS1PAADCyclopamineEAG1.7347e-02-0.4715image
chr12:93542505-93543137:-PAADCyclopamineEER1.7347e-02-0.4715image
ENSG00000246985.6,SOCS2-AS1PCPGCHIR.99021EAG1.4078e-03-0.2535image
chr12:93542505-93543137:-PCPGCHIR.99021EER1.4022e-03-0.2536image
chr12:93542505-93543137:-PRADEHT.1864EER7.7900e-070.2208image
ENSG00000246985.6,SOCS2-AS1PRADEHT.1864EAG2.3159e-060.2111image
chr12:93542505-93543137:-SARCMG.132EER1.5233e-030.3466image
ENSG00000246985.6,SOCS2-AS1SARCMG.132EAG8.3314e-040.3641image
chr12:93542505-93543137:-SKCMDocetaxelEER4.7788e-030.2549image
ENSG00000246985.6,SOCS2-AS1SKCMDocetaxelEAG4.6959e-030.2554image
ENSG00000246985.6,SOCS2-AS1STADBAY.61.3606EAG3.7808e-02-0.2231image
chr12:93542505-93543137:-STADATRAEER8.7112e-03-0.2812image
ENSG00000246985.6,SOCS2-AS1THCAElesclomolEAG7.2577e-030.2449image
chr12:93542505-93543137:-THCAElesclomolEER7.2577e-030.2449image
chr12:93542505-93543137:-THYMEmbelinEER3.2326e-04-0.3746image
ENSG00000246985.6,SOCS2-AS1THYMEmbelinEAG3.2006e-04-0.3749image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType